ESG

A new medical device enters real-world trials, promising to solve a critical failure point in dialysis grafts and improve life for millions of patients.

A new partnership integrates whole-genome sequencing into a clinical trial for a novel cancer drug, promising to accelerate development and usher in a new era.

Transamerica and Empathy's new partnership signals a shift in insurance, offering comprehensive logistical and emotional support beyond a simple claim check.

After reporting huge preliminary profit and revenue growth, Sagtec unveils a bold 2026 strategy focused on AI platforms, EV subscriptions, and ESG tech.

EnterpriseDB is gaining major clients as companies race to adopt AI while keeping tight control over their data, avoiding vendor lock-in with open-source tech.

Over 60% of cats and 59% of dogs are overweight, a silent crisis shortening lives. Vets warn against risky shortcuts and urge proactive, guided care.

A new grant funds a radical approach using AI and postmortem human brains to find crucial clues for Parkinson's therapies, aiming to crack a major medical challenge.

Dr. Marinna Madrid's new role at Cellino signals a new era for AI in medicine, as she builds both the tech and the regulatory roadmap for personalized therapies.

TPG's CFO Jack Weingart will address top investors, with analysts watching for signals on growth, deal-making, and navigating a complex global economy.

A new initiative offers free training for 15,000 home health aides, a strategic move to solve a critical workforce shortage and bolster care for millions.

As NAPCO prepares its Q2 results, investors watch if its high-margin service revenue can offset market volatility and solidify its edge in school safety.

A landmark FDA decision allows Life Biosciences to test its epigenetic reprogramming therapy, ER-100, offering new hope for restoring sight in the blind.

As drug-resistant fungi pose a grave threat, SCYNEXIS presents promising data on SCY-247, a next-gen drug that could redefine the fight against infection.

A new SoHo wellness hub uses invisible tech and EEG sensors to read your mind and adapt its environment. But is this the future or a privacy nightmare?

With promising brain scan data, a deep therapeutic pipeline, and a cash runway into 2027, Radiopharm Theranostics is gaining significant momentum.

A new study in Nature Medicine shows a fasting-mimicking diet led to high remission rates in Crohn's patients, heralding a new era for 'Food as Medicine'.

With new funding, Stellular Bio is advancing an 'off-the-shelf' biologic therapy, offering new hope for Sjogren's patients and beyond.

A historic wave of business acquisitions is set to reshape Canada's economy as owners retire, unlocking immense profits for savvy buyers.

Travel is no longer just about the destination. In 2026, AI-powered planning and a thirst for authentic experiences are reshaping vacations worldwide.

Finnish firm GlucoModicum publishes research validating its needle-free tech, a major step toward ending painful finger pricks for diabetes management.